Allogene, Overland woo an experienced hand from WuXi to steer their allogeneic CAR-T JV

Amber Tong

Allogene Overland Biopharm, the joint venture David Chang and Ed Zhang set up to turbocharge the development of off-the-shelf CAR-T therapies in China, has locked …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Allogene, Overland woo an experienced hand from WuXi to steer their allogeneic CAR-T JV

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump 2.0 blog: Wayback Machine is insufficient for US health data, judge says

Travere plans to seek expanded label for kidney drug despite failed trial

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Biohaven lands priority review on second-chance application for neurodegenerative drug

What will pharma's share buyback shopping spree mean for M&A?

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Al­lo­gene, Over­land woo an ex­pe­ri­enced hand from WuXi to steer their al­lo­gene­ic CAR-T JV

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Allogene, Overland woo an experienced hand from WuXi to steer their allogeneic CAR-T JV